Search

Your search keyword '"Curial, Chantall"' showing total 14 results
Start Over Author "Curial, Chantall"
14 results on '"Curial, Chantall"'

1. A 21‐bp deletion in the complement regulator CD55 promotor region is associated with multifocal motor neuropathy and its disease course

Author

Bos, Jeroen W., primary, Groen, Ewout J. N., additional, Otten, Henny G., additional, Budding, Kevin, additional, van Eijk, Ruben P. A., additional, Curial, Chantall, additional, Kardol‐Hoefnagel, Tineke, additional, Goedee, H. Stephan, additional, van den Berg, Leonard H., additional, and van der Pol, W. Ludo, additional

Published
2024
Full Text
View/download PDF

2. A 21-bp deletion in the complement regulator CD55 promotor region is associated with multifocal motor neuropathy and its disease course

Author

Opleiding Neurologie, CTI, CDL Cluster Speciële Diagnostiek, Infection & Immunity, CTI Budding, Datamanagement Team 1, Projectafdeling ALS, Brain, CTI Otten, Neurologen, Regenerative Medicine and Stem Cells, Bos, Jeroen W., Groen, Ewout J.N., Otten, Henny G., Budding, Kevin, van Eijk, Ruben P.A., Curial, Chantall, Kardol-Hoefnagel, Tineke, Goedee, H. Stephan, van den Berg, Leonard H., van der Pol, W. Ludo, Opleiding Neurologie, CTI, CDL Cluster Speciële Diagnostiek, Infection & Immunity, CTI Budding, Datamanagement Team 1, Projectafdeling ALS, Brain, CTI Otten, Neurologen, Regenerative Medicine and Stem Cells, Bos, Jeroen W., Groen, Ewout J.N., Otten, Henny G., Budding, Kevin, van Eijk, Ruben P.A., Curial, Chantall, Kardol-Hoefnagel, Tineke, Goedee, H. Stephan, van den Berg, Leonard H., and van der Pol, W. Ludo

Published
2024

3. Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy

Author

Budding, Kevin, Johansen, Lill Eva, Van de Walle, Inge, Dijkxhoorn, Kim, de Zeeuw, Elisabeth, Bloemenkamp, Lauri M., Bos, Jeroen W., Jansen, Marc D., Curial, Chantall A.D., Silence, Karen, de Haard, Hans, Blanchetot, Christophe, Van de Ven, Liesbeth, Leusen, Jeanette H.W., Pasterkamp, R. Jeroen, van den Berg, Leonard H., Hack, C. Erik, Boross, Peter, and van der Pol, W. Ludo

Published
2022
Full Text
View/download PDF

5. Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy

Author

CTI Budding, Infection & Immunity, Projectafdeling ALS, Opleiding Neurologie, CTI Leusen, Cancer, Translational Neuroscience, Brain, Regenerative Medicine and Stem Cells, Neurologen, CTI, Budding, Kevin, Johansen, Lill Eva, Van de Walle, Inge, Dijkxhoorn, Kim, de Zeeuw, Elisabeth, Bloemenkamp, Lauri M., Bos, Jeroen W., Jansen, Marc D., Curial, Chantall A.D., Silence, Karen, de Haard, Hans, Blanchetot, Christophe, Van de Ven, Liesbeth, Leusen, Jeanette H.W., Pasterkamp, R. Jeroen, van den Berg, Leonard H., Hack, C. Erik, Boross, Peter, van der Pol, W. Ludo, CTI Budding, Infection & Immunity, Projectafdeling ALS, Opleiding Neurologie, CTI Leusen, Cancer, Translational Neuroscience, Brain, Regenerative Medicine and Stem Cells, Neurologen, CTI, Budding, Kevin, Johansen, Lill Eva, Van de Walle, Inge, Dijkxhoorn, Kim, de Zeeuw, Elisabeth, Bloemenkamp, Lauri M., Bos, Jeroen W., Jansen, Marc D., Curial, Chantall A.D., Silence, Karen, de Haard, Hans, Blanchetot, Christophe, Van de Ven, Liesbeth, Leusen, Jeanette H.W., Pasterkamp, R. Jeroen, van den Berg, Leonard H., Hack, C. Erik, Boross, Peter, and van der Pol, W. Ludo

Published
2022

6. Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy

Author

Budding, Kevin, primary, Johansen, Lill Eva, additional, Van de Walle, Inge, additional, Dijkxhoorn, Kim, additional, de Zeeuw, Elisabeth, additional, Bloemenkamp, Lauri M., additional, Bos, Jeroen W., additional, Jansen, Marc D., additional, Curial, Chantall A.D., additional, Silence, Karen, additional, de Haard, Hans, additional, Blanchetot, Christophe, additional, Van de Ven, Liesbeth, additional, Leusen, Jeanette H.W., additional, Pasterkamp, R. Jeroen, additional, van den Berg, Leonard H., additional, Hack, C. Erik, additional, Boross, Peter, additional, and van der Pol, W. Ludo, additional

Published
2021
Full Text
View/download PDF

7. SMN1 Duplications Are Associated With Progressive Muscular Atrophy, but Not With Multifocal Motor Neuropathy and Primary Lateral Sclerosis

Author

Bos, Jeroen W., primary, Groen, Ewout J.N., additional, Wadman, Renske I., additional, Curial, Chantall A.D., additional, Molleman, Naomi N., additional, Zegers, Marinka, additional, van Vught, Paul W.J., additional, Snetselaar, Reinier, additional, Vijzelaar, Raymon, additional, van der Pol, W. Ludo, additional, and van den Berg, Leonard H., additional

Published
2021
Full Text
View/download PDF

8. PATHOLOGICAL VALIDATION OF ADJUVANT ANTI - FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR PERSONALIZED TREATMENT OF BLADDER CANCER: MP28-20

Author

NEUZILLET, Yann, MERTENS, Laura, SHARIAT, Shahrokh, BOSTROM, Peter, MIRTTI, Tuomas, SAGALOWSKY, Arthur, ASHFAQ, Raheela, BROEKS, Annegien, VAN, Michiel, HEIJDEN, DER, PETERS, Dennis, CURIAL, Chantall, JONG, Jeroen DE, HORENBLAS, Simon, HURST, Carolyn, TOMLINSON, Darren, KNOWLES, Margaret, BAPAT, Bharati, JEWETT, Michael, ZLOTTA, Alexandre, SANDERS, Joyce, LOTAN, Yair, KWAST, Theo VAN DER, and RHIJN, Bas VAN

Published
2014
Full Text
View/download PDF

9. Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy

Author

ZL Neuromusculaire Ziekten Medisch, Projectafdeling ALS, Opleiding Neurologie, Brain, Regenerative Medicine and Stem Cells, Wadman, Renske I, Jansen, Marc D, Stam, Marloes, Wijngaarde, Camiel A, Curial, Chantall A D, Medic, Jelena, Sodaar, Peter, Schouten, Jan, Vijzelaar, Raymon, Lemmink, Henny H, van den Berg, Leonard H, Groen, Ewout J N, van der Pol, W Ludo, ZL Neuromusculaire Ziekten Medisch, Projectafdeling ALS, Opleiding Neurologie, Brain, Regenerative Medicine and Stem Cells, Wadman, Renske I, Jansen, Marc D, Stam, Marloes, Wijngaarde, Camiel A, Curial, Chantall A D, Medic, Jelena, Sodaar, Peter, Schouten, Jan, Vijzelaar, Raymon, Lemmink, Henny H, van den Berg, Leonard H, Groen, Ewout J N, and van der Pol, W Ludo

Published
2020

10. Analysis of FUS, PFN2, TDP-43, and PLS3 as potential disease severity modifiers in spinal muscular atrophy

Author

ZL Neuromusculaire Ziekten Medisch, Other research (not in main researchprogram), Projectafdeling ALS, Opleiding Neurologie, Brain, Neurogenetica, Genetica Sectie Genoomdiagnostiek, Regenerative Medicine and Stem Cells, Wadman, Renske I, Jansen, Marc D, Curial, Chantall A D, Groen, Ewout J N, Stam, Marloes, Wijngaarde, Camiel A, Medic, Jelena, Sodaar, Peter, van Eijk, Kristel R, Huibers, Manon M H, van Kuik, Joyce, Lemmink, Henny H, van Rheenen, Wouter, Veldink, Jan Herman, van den Berg, Leonard H, van der Pol, W Ludo, ZL Neuromusculaire Ziekten Medisch, Other research (not in main researchprogram), Projectafdeling ALS, Opleiding Neurologie, Brain, Neurogenetica, Genetica Sectie Genoomdiagnostiek, Regenerative Medicine and Stem Cells, Wadman, Renske I, Jansen, Marc D, Curial, Chantall A D, Groen, Ewout J N, Stam, Marloes, Wijngaarde, Camiel A, Medic, Jelena, Sodaar, Peter, van Eijk, Kristel R, Huibers, Manon M H, van Kuik, Joyce, Lemmink, Henny H, van Rheenen, Wouter, Veldink, Jan Herman, van den Berg, Leonard H, and van der Pol, W Ludo

Published
2020

11. Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy

Author

Wadman, Renske I, primary, Jansen, Marc D, additional, Stam, Marloes, additional, Wijngaarde, Camiel A, additional, Curial, Chantall A D, additional, Medic, Jelena, additional, Sodaar, Peter, additional, Schouten, Jan, additional, Vijzelaar, Raymon, additional, Lemmink, Henny H, additional, van den Berg, Leonard H, additional, Groen, Ewout J N, additional, and van der Pol, W Ludo, additional

Published
2020
Full Text
View/download PDF

12. MP28-20 PATHOLOGICAL VALIDATION OF ADJUVANT ANTI - FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR PERSONALIZED TREATMENT OF BLADDER CANCER

Author

NEUZILLET, Yann, primary, MERTENS, Laura, additional, SHARIAT, Shahrokh, additional, BOSTROM, Peter, additional, MIRTTI, Tuomas, additional, SAGALOWSKY, Arthur, additional, ASHFAQ, Raheela, additional, BROEKS, Annegien, additional, VAN, Michiel, additional, HEIJDEN, DER, additional, PETERS, Dennis, additional, CURIAL, Chantall, additional, JONG, Jeroen DE, additional, HORENBLAS, Simon, additional, HURST, Carolyn, additional, TOMLINSON, Darren, additional, KNOWLES, Margaret, additional, BAPAT, Bharati, additional, JEWETT, Michael, additional, ZLOTTA, Alexandre, additional, SANDERS, Joyce, additional, LOTAN, Yair, additional, KWAST, Theo VAN DER, additional, and RHIJN, Bas VAN, additional

Published
2014
Full Text
View/download PDF

13. Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy.

Author

Budding K, Johansen LE, Van de Walle I, Dijkxhoorn K, de Zeeuw E, Bloemenkamp LM, Bos JW, Jansen MD, Curial CAD, Silence K, de Haard H, Blanchetot C, Van de Ven L, Leusen JHW, Pasterkamp RJ, van den Berg LH, Hack CE, Boross P, and van der Pol WL

Subjects
Cells, Cultured, Humans, Immunoglobulin M, Induced Pluripotent Stem Cells, Antibodies, Monoclonal, Humanized pharmacology, Complement Activation immunology, Complement C2 drug effects, Motor Neurons, Polyneuropathies drug therapy, Polyneuropathies immunology
Abstract

Background and Objectives: To determine the role of complement in the disease pathology of multifocal motor neuropathy (MMN), we investigated complement activation, and inhibition, on binding of MMN patient-derived immunoglobulin M (IgM) antibodies in an induced pluripotent stem cell (iPSC)-derived motor neuron (MN) model for MMN., Methods: iPSC-derived MNs were characterized for the expression of complement receptors and membrane-bound regulators, for the binding of circulating IgM anti-GM1 from patients with MMN, and for subsequent fixation of C4 and C3 on incubation with fresh serum. The potency of ARGX-117, a novel inhibitory monoclonal antibody targeting C2, to inhibit fixation of complement was assessed., Results: iPSC-derived MNs moderately express the complement regulatory proteins CD46 and CD55 and strongly expressed CD59. Furthermore, MNs express C3aR, C5aR, and complement receptor 1. IgM anti-GM1 antibodies in serum from patients with MMN bind to MNs and induce C3 and C4 fixation on incubation with fresh serum. ARGX-117 inhibits complement activation downstream of C4 induced by patient-derived anti-GM1 antibodies bound to MNs., Discussion: Binding of IgM antibodies from patients with MMN to iPSC-derived MNs induces complement activation. By expressing complement regulatory proteins, particularly CD59, MNs are protected against complement-mediated lysis. Yet, because of expressing C3aR, the function of these cells may be affected by complement activation upstream of membrane attack complex formation. ARGX-117 inhibits complement activation upstream of C3 in this disease model for MMN and therefore represents an intervention strategy to prevent harmful effects of complement in MMN., (Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)

Published
2021
Full Text
View/download PDF

14. Analysis of FUS , PFN2, TDP-43 , and PLS3 as potential disease severity modifiers in spinal muscular atrophy.

Author

Wadman RI, Jansen MD, Curial CAD, Groen EJN, Stam M, Wijngaarde CA, Medic J, Sodaar P, van Eijk KR, Huibers MMH, van Kuik J, Lemmink HH, van Rheenen W, Veldink JH, van den Berg LH, and van der Pol WL

Abstract

Objective: To investigate mutations in genes that are potential modifiers of spinal muscular atrophy (SMA) severity., Methods: We performed a hypothesis-based search into the presence of variants in fused in sarcoma ( FUS ) , transactive response DNA-binding protein 43 ( TDP-43 ), plastin 3 ( PLS3 ), and profilin 2 ( PFN2 ) in a cohort of 153 patients with SMA types 1-4, including 19 families. Variants were detected with targeted next-generation sequencing and confirmed with Sanger sequencing. Functional effects of the identified variants were analyzed in silico and for PLS3, by analyzing expression levels in peripheral blood., Results: We identified 2 exonic variants in FUS exons 5 and 6 (p.R216C and p.S135N) in 2 unrelated patients, but clinical effects were not evident. We identified 8 intronic variants in PLS3 in 33 patients. Five PLS3 variants (c.1511+82T>C; c.748+130 G>A; c.367+182C>T; c.891-25T>C (rs145269469); c.1355+17A>G (rs150802596)) potentially alter exonic splice silencer or exonic splice enhancer sites. The variant c.367+182C>T, but not RNA expression levels, corresponded with a more severe phenotype in 1 family. However, this variant or level of PLS3 expression did not consistently correspond with a milder or more severe phenotype in other families or the overall cohort. We found 3 heterozygous, intronic variants in PFN2 and TDP-43 with no correlation with clinical phenotype or effects on splicing., Conclusions: PLS3 and FUS sequence variants do not modify SMA severity at the population level. Specific variants in individual patients or families do not consistently correlate with disease severity., (Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results